Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares > Very informative article from director of Tribute
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by kuatoliveson Aug 18, 2016 3:07pm
82 Views
Post# 25155522

RE:RE:RE:RE:RE:RE:RE:Very informative article from director of Tribute

RE:RE:RE:RE:RE:RE:RE:Very informative article from director of TributeThe issue is with former Tribute management, not current Aralez management - minus Harris who should go.   Whatever comments are made (or drug approvals such as Bilastine are realized) are insignificant compared to the result of the FDA decision.... wich is kinda the point so... I don't think I'm doing ARLZ any disservice by informing investors of Tribute's past. It's prologue, something we all - especially myself - have to accept.

I hope he's right, I really do. .I'd rather be rich with some scMMbag former Tribute exec who was given his shares telling me what a great job he did -  versus being poor and right.

However,  I see no point in continuing arguing with him beyond my existing comments. That'll be it for me.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities